Wall Street brokerages forecast that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will report $6.92 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for Pieris Pharmaceuticals’ earnings, with the highest sales estimate coming in at $8.80 million and the lowest estimate coming in at $4.50 million. Pieris Pharmaceuticals posted sales of $18.15 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 61.9%. The company is expected to report its next earnings results on Friday, March 8th.
On average, analysts expect that Pieris Pharmaceuticals will report full year sales of $31.11 million for the current year, with estimates ranging from $28.70 million to $33.00 million. For the next fiscal year, analysts forecast that the company will post sales of $20.32 million, with estimates ranging from $12.00 million to $31.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover Pieris Pharmaceuticals.
PIRS has been the topic of a number of research analyst reports. Cowen reiterated a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Sunday, November 11th. BidaskClub downgraded Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 26th. HC Wainwright set a $5.00 target price on Pieris Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Finally, ValuEngine downgraded Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $10.00.
Shares of NASDAQ:PIRS traded up $0.08 during mid-day trading on Tuesday, reaching $3.07. The stock had a trading volume of 369,202 shares, compared to its average volume of 370,022. The company has a market capitalization of $157.58 million, a P/E ratio of -7.68 and a beta of 1.87. Pieris Pharmaceuticals has a 1 year low of $2.39 and a 1 year high of $9.13.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Read More: Diversification For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.